Conclusion of non-exclusive discount agreements pursuant to Section 130a (8) of the German Social Code (SGB) on medicinal products with the active substance distigmine (N07AA03) within the period from 1.7.2021 to 30.6.2023 with the possibility of concluding contracts at any time (open-house model).

The AOK Rheinland-Pfalz/Saarland — Die Gesundheitskasse offers all interested pharmaceutical companies, without any choice of discount, discount agreements with the active substance distigmine (N07AA03). The contracts are concluded within the framework of an “open house model”. The contracts offered are not exclusive; contracts with all market participants (pharmaceutical companies) are requested by AOK Rhineland-Palatinate/Saarland — Die Gesundheitskasse. In the Open House model, all participants have uniform conditions. The content of the contract, conditions and access procedures are uniform — individual negotiations are not conducted.

The contract terms are a maximum of 24 months, the earliest start of the contract is 1.7.2021. All contracts shall expire no later than 24 months after the date of the earliest commencement of the contract, irrespective of the date of the contract. An entry or conclusion of a contract may take place on the first of each month within the 24-month period.

There is a right of termination 6 weeks at the end of each month in accordance with the provisions of the contract. Further information on the termination options can be found in the contract documents.

The AOK Rhineland-Palatinate / Saarland - The health insurance company reserves the right to replace the non-exclusive open house discount contracts with exclusive discount contracts during the contract period within the framework of Europe-wide tendering procedures. With the entry into force of exclusive discount contracts, the open house contracts are terminated in accordance with the contractual regulation, ie the open house contracts end automatically.

Interested pharmaceutical companies may request the participation documents and the contract documents from the contact address referred to in I.1). Contracts for the active substance distigmine (N07AA03) will be concluded for the first time with effect from 1.7.2021. Interested parties wishing to become a contractual partner on this date must submit the contract documents to be submitted to AOK Rhineland-Palatinate/Saarland — Die Gesundheitskasse by 31 May 2021. Access to the AOK Rhineland-Palatinate/Saarland — Die Gesundheitskasse is important.

Note: The first award in this procedure will be granted no earlier than 10 calendar days after the publication of this EU announcement in the Official Journal. Later contracts can be concluded on the first of a month during the twenty-four-month maximum term. For interested parties who would like to become contractual partners on these follow-up dates, the receipt of the contract documents including Appendix 1 must be submitted no later than the end of the month preceding the previous month of the desired start of the contract (e.g. receipt April 30th when the contract starts June 1st). The exact entry deadlines will be announced with the contract documents. This publication is not a public contract within the meaning of the procurement coordination directive 2014/24 / EU of the European Parliament and of the Council or of public procurement law. In order to ensure the greatest possible degree of transparency for the intended contracts, the publication is published in the supplement to the Official Journal of the European Union. In the absence of a corresponding publication form, the contract notice will be used. The resulting conceptual requirements, such as the process name "Open Procedure", are solely due to the use of this notice form and the publication platform. This is not associated with any further significance, in particular submission to procurement regulations, unless they are mandatory for legal reasons.